AVXL
ANAVEX LIFE SCIENCES CORP.
No net buying or selling imbalance over the last 3 months
No net buyers or sellers account for the net balance. There is no cluster of three distinct buyers within 30 days. We found no CEO/CFO purchases over 12 months.
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
$0.00
0 buyers · 0 sellers
12-month purchases
$0.00
0 distinct insiders
12-month sales
$0.00
0 distinct insiders
Highlighted alerts
0
0 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
No executive purchases found
Get AVXL insider trades by API
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
AVXL overview: breakout setup, X sentiment and insiders in one page →
The value is in what we do not call a signal.
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
- Code
- A
- Shares
- 25,000
- Price
- $0.00
- Footnotes
- 1
As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.
Recent transactions
Voluntary purchases and sales; administrative noise stays hidden.